In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus

  • Allison B. Goldfine
  • Donald C. Simonson
  • Franco Folli
  • Mary-Elizabeth Patti
  • C. Ronald Kahn
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 16)


In vivo vanadate and vanadyl have been shown to mimic the action of insulin and to be effective treatment for animal models of both Type I and Type II diabetes. The molecular mechanism of action of the vanadium salts on insulin sensitivity remains uncertain, and several potential sites proposed for the insulin-like effects are reviewed. In human trials, insulin sensitivity improved in patients with NIDDM, as well as in some patients with IDDM after two weeks of treatment with sodium metavanadate. This increase in insulin sensitivity was primarily due to an increase in non-oxidative glucose disposal, whereas oxidative glucose disposal and both basal and insulin stimulated suppression of hepatic glucose output (HGP) were unchanged. Clinically, oral vanadate was associated with a small decrease in insulin requirements in IDDM subjects. Of additional benefit, there was a decrease in total cholesterol levels in both IDDM and NIDDM subjects. Furthermore, there was an increase in the basal activities of MAP and S6 kinases to levels similar to the insulin-stimulated levels in controls, but there was little or no further stimulation with insulin was seen. Further understanding of the mechanism of vanadium action may ultimately be useful in the design of drugs that improve glucose tolerance.

Key words

vanadate vanadium insulin dependent diabetes mellitus noninsulin dependent diabetes mellitus mechanism of action phophatases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nechay BR, Nanninga LB, Nechay PSE, Post RL, Grantham JJ, Macara IG, Kubena LF, Phillips TD, Nielsen FH: Role of vanadium in biology. Fed Proc45: 123–132, 1986Google Scholar
  2. 2.
    Lyonett, Martz, Martin: L’emploithérapeutique de derivés du vanadium. La Presse Medicale: 191–192, 1899Google Scholar
  3. 3.
    Dubyak GR, Kleinzeller A: The insulin-mimetic effects of vanadate as a Na-K ATPase inhibitor. J Biol Chem 255: 5306–5312, 1980PubMedGoogle Scholar
  4. 4.
    Shechter Y, Karlish SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 284: 556–558, 1980PubMedCrossRefGoogle Scholar
  5. 5.
    Dlouha H, Teisinger T, Vyskocil F: The effect of vanadate on the electrogenic Na+/K pump, intracellular Na+ concentration and electrophysiological characteristics of mouse skeletal muscle fiber. Physiol Bohemoslov 30: 1–10, 1981PubMedGoogle Scholar
  6. 6.
    Shechter Y, Ron A: Effect of depletion of bicarbonate or phosphate ions on insulin action in rat adipocytes. Further characterization of the receptor-effector system. J Biol Chem 261: 14951–14954, 1986PubMedGoogle Scholar
  7. 7.
    Degani H, Gochin M, Karlish SJD, ShechterY: Electron paramagnetic studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry 20: 5795–5799, 1981PubMedCrossRefGoogle Scholar
  8. 8.
    Tamura S, Brown TA, Dubler RE, Larner J: Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochemical & Biophysical Research Communications 113: 80–86, 1983CrossRefGoogle Scholar
  9. 9.
    Werdan K, Bauriedel G, Fisher B, Krawietz W, Erdmann E, Schmitz W, Scholz H: Stimulatory and inhibitory action of vanadate on potassium uptake and cellular sodium and potassium in heart cells in culture. Biochim Biophys Acta 23: 79–83, 1982Google Scholar
  10. 10.
    Hori C, Oka T: Vanadate enhances the stimulatory action of insulin on DNA synthesis in cultured mouse mammary gland. Biochim Biophys Acta 610: 235–240, 1980PubMedGoogle Scholar
  11. 11.
    Smith JB: Vanadium ions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells. Proc Natl Acad Sci (USA) 80: 6162–6166, 1983CrossRefGoogle Scholar
  12. 12.
    Canalis E: Effect of sodium vanadate on deoxyribonucleic acid and protein synthesis on cultured rat clavaria. Endocrinology 116: 855–862, 1985PubMedCrossRefGoogle Scholar
  13. 13.
    Shechter Y: Insulin mimetic effects of vanadate: possible implications for future treatment of diabetes. Diabetes 39: 1–5, 1990PubMedCrossRefGoogle Scholar
  14. 14.
    Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin dependent diabetes mellitus. J Clin Invest 87: 1286–1294, 1991PubMedCrossRefGoogle Scholar
  15. 15.
    Brichard SM, Baily CJ, Henquin JC: Long term improvement of glucose homeostatis by vanadate in obese hyperinsulin fa/fa rats. Endocrinology 125: 2510–2516, 1989PubMedCrossRefGoogle Scholar
  16. 16.
    Brichard SM, Baily CJ, Henquin JC: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326–1332, 1990PubMedCrossRefGoogle Scholar
  17. 17.
    Ramanadham S, Mongold JJ, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257: H904–911, 1989PubMedGoogle Scholar
  18. 18.
    Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474–1477, 1985PubMedCrossRefGoogle Scholar
  19. 19.
    Meyerovitch J, Backer JM, Kahn CR: Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J Clin Invest 84: 976–983, 1989PubMedCrossRefGoogle Scholar
  20. 20.
    Battell ML, Yuen VG, McNeill JH: Treatment of BB rats with vanadyl sulphate. Pharma Commun 1(4): 291–301, 1992Google Scholar
  21. 21.
    Gil J, Miralpeix M, Carreras J, Bartrons R: Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-busphosphate levels in the liver of diabetic rats. J Biol Chem 263: 1868–1871, 1988PubMedGoogle Scholar
  22. 22.
    Ramanadham S, Brownsey RW, Cros GH, Mongold JJ, McNeill JH: Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 38: 1022–1028, 1989PubMedCrossRefGoogle Scholar
  23. 23.
    Brichard SM, Omgemta LN, Henquin JC: Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35: 522–527, 1990CrossRefGoogle Scholar
  24. 24.
    Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem 262: 6658–6662, 1987PubMedGoogle Scholar
  25. 25.
    Flier JS: Lilly Lecture: Syndromes of insulin resistance. From patient to gene and back again. Diabetes 41: 1207–1219, 1992PubMedCrossRefGoogle Scholar
  26. 26.
    Kahn CR: Causes of insulin resistance. Nature 373: 384–385, 1995PubMedCrossRefGoogle Scholar
  27. 27.
    Rothenberg PL, Lane WS, Karasik A, Backer J, White M, Kahn CR: Purification and partial sequence analysis of pp 185, the major cellular substrate of the insulin receptor tyrosine kinase. J Biol Chem 266: 8302–8311, 1991PubMedGoogle Scholar
  28. 28.
    Sun X, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF: The structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73–77, 1991PubMedCrossRefGoogle Scholar
  29. 29.
    Koch CA, Anderson DJ, Moran MF, Ellis C, Pawson T: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668–674, 1991PubMedCrossRefGoogle Scholar
  30. 30.
    Gould GW, Derechin V, James DE, Tordjman K, Ahern S, Gibbs EM, Lienhard GE, Mueckler M: Insulin-stimulated translocation of the HepG2/erythrocyte-type glucose transporter expressed in 3T3-L1 adipocytes. J Biol Chem 264: 2180–2184, 1989PubMedGoogle Scholar
  31. 31.
    Cormont M, Tanti JF, Zahraoui A, Vanobberghen E, Tavitian A, LeMarchand-Brustel Y: Insulin and okadaic acid induce Rab4 redistribution in adipocytes. J Biol Chem 268(26): 19491–19497, 1993PubMedGoogle Scholar
  32. 32.
    Berman M, McGuire EA, Roth J, Zeleznik AJ: Kinetic modeling of insulin binding to receptors and degradation in vivo in rabbits. Diabetes 29: 50–59, 1980PubMedGoogle Scholar
  33. 33.
    Fischer EH, Charbonneau H, Tonks NK: Protein tyrosine phosphatases-a diverse family of intracellular and transmembrane enzymes. Science 253: 401–406, 1991PubMedCrossRefGoogle Scholar
  34. 34.
    Papoulas O, Williams NG, Kingston RE: DNA binding activation of c-Myc purified from eukoryotic cells. J Biol Chem 267: 10470–10480, 1992PubMedGoogle Scholar
  35. 35.
    Tamura S, Brown TA, Whipple JH, Fujita-Yamaguchi Y, Dubler RE, Cheng K, Larner J: A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem 259: 6650–6658, 1984PubMedGoogle Scholar
  36. 36.
    Strout HV, Vicario PP, Saperstein R, Slater EE: The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. Endocrinology 124: 1918–1924, 1989PubMedCrossRefGoogle Scholar
  37. 37.
    Green A: The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem J 238: 663–669, 1986PubMedGoogle Scholar
  38. 38.
    Shisheva A, Shechter Y: Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 31: 8059–8063, 1992PubMedCrossRefGoogle Scholar
  39. 39.
    Shisheva A, Shechter YA: Ccytosolic protein tyrsoine kinase in rat adipocytes. FEBS Lett 300: 93–96, 1982CrossRefGoogle Scholar
  40. 40.
    Kadota S, Fantus GI, Deragon G, Guyda HJ, Hersh B, Posner BI: Peroxide(s) of vanadium: a novel and potent insulin-mimetic agent which activates the insulin receptor kinase. Biochem Biophys Res Commun 147: 259–266, 1987PubMedCrossRefGoogle Scholar
  41. 41.
    Goldstein BJ: Protein-tyrosine phosphatase and the regulation of insulin action. J Cell Biochem 48: 33–42, 1992PubMedCrossRefGoogle Scholar
  42. 42.
    Sale GJ: Anonymous Advances in Protein Phosphatases. 6th ed. Insulin receptor phosphotyrosyl protein phosphatases and the regulation of insulin receptor tyrosine kinase action. 1991, pp 159–186Google Scholar
  43. 43.
    Swarup G, Cohen S, Garbers DL: Inhibition of membrane phosphotyrosyl protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107: 1104–1109, 1982PubMedCrossRefGoogle Scholar
  44. 44.
    Meyerovitch J, Backer JM, Csermely P, Shoelson SE, Kahn CR: Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells. Biochemistry 31: 10338–10344, 1992PubMedCrossRefGoogle Scholar
  45. 45.
    Burant CF, Treutelaar MK, Buse MG: Diabetes-induced functional and structural changes in insulin receptors from rat skeletal muscle. J Clin Invest 77: 260–270, 1986PubMedCrossRefGoogle Scholar
  46. 46.
    Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, Thomas F, Jenquin M, Silverman JF, Khazanie PG, Sinha MK: Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. J Clin Invest 78: 249–258, 1986PubMedCrossRefGoogle Scholar
  47. 47.
    Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM: Decreased kinase activity of insulin receptors from adipocytes of non-insulin dependent diabetic subjects. J Clin Invest 79: 240–250, 1987PubMedCrossRefGoogle Scholar
  48. 48.
    Arner P, PollareT, Lithell H, Livingston JN: Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and Type II (noninsulin-dependent) diabetes mellitus. Diabetologia 30: 437–440, 1987PubMedCrossRefGoogle Scholar
  49. 49.
    Ueki H, Okuhama R, Sera M, Inoue T, Tominaga N, Mori ta T: Stimulatory affect of vanadage on 3′,5′-cyclic guanosine monophosphate-inhibited low Michaelis-Menten constant 3′,5′-cyclic adenosine monophosphate phosphodiesterase activity in isolated rat fat pads. Endocrinology 131: 441–446, 1992PubMedCrossRefGoogle Scholar
  50. 50.
    Souness JE, Maslen C, Scott LC: Effects of solubilization and vanadate\glutathione complex on inhibitor potencies agains eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett 302: 181–184, 1992PubMedCrossRefGoogle Scholar
  51. 51.
    Soll AH, Kahn CR, Neville DM, Jr.: Insulin binding to liver plasma membranes in the obese hyperglycemic (ob/ob) mouse: Demonstration of a decreased number of functionally normal receptors. J Biol Chem 250: 7402–7407, 1975Google Scholar
  52. 52.
    Brichard SM, Assimacopoulos-Jeannet F, Jeanrenaud B: Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression. Endocrinology 131: 311–317, 1992PubMedCrossRefGoogle Scholar
  53. 53.
    Paquet MR, Romanek RJ, Sargeant RJ: Vanadate induces the recruitment of GLUT-4 glucose transporter to the plasma membrane of rat adipocytes. Mol Cell Biochem 109: 149–155, 1992PubMedCrossRefGoogle Scholar
  54. 54.
    Ferber S, Meyerovitch J, Kriauciunas KM, Kahn CR: Vanadate normalizes hyperglycemia and PEPCK mRNA levels in ob/ob mice. (In Press) Metabolism 1994Google Scholar
  55. 55.
    DeFronzo RA, Robin JD, Andres R: Glucose clamp techniques: a method for quantifying insulin secreation and resistance. Am J Physiol 237: E214–223, 1979PubMedGoogle Scholar
  56. 56.
    Ferrannini E, DelPrato S, DeFronzo RA: Glucose kinetics and tracer methods. In: Clarke WL, Larner J and Pohl SL (eds). Methods in Diabetics Research. Vol II, Clinical Methods. Canada: Wiley Interscience, 1986Google Scholar
  57. 57.
    Ferrannini E: The theoretical basis of indirect calorimetry: A review. Metabolism 37: 287–301, 1988PubMedCrossRefGoogle Scholar
  58. 58.
    Simonson DC, DeFronzo RA: Indirect calorimetry: methodological and interpretative problems. Am J Physiol 258: E399–412, 1990PubMedGoogle Scholar
  59. 59.
    Curran GL, Azarnoff DL, Bolinger RE: Effect of cholesterol synthesis inhibition in normocholesteremic young men. J Clin Invest: 1251–1261, 1959Google Scholar
  60. 60.
    Muggeo M, Bar RS, Roth J et al.: Insulin receptors: Biologically relevant regulation of concentration and affinity. In: Miescher PA, (ed). Menarini Series on Immunopathy: First Symposium on Organ Specific Autoimmunity. Schwabe and Company, Basel, 1978, pp 149–159Google Scholar
  61. 61.
    Maher DW, Davis I, Boyd AW, Morstyn G: Human interleukin-4: an immunomodulator with potential therapeutic applications. Progress in Growth Factor Research 3: 43–56, 1991PubMedCrossRefGoogle Scholar
  62. 62.
    Tobe K, Kadowaki T, Hara K et al.: Sequential activation of MAP kinase activator, MAP kinases, and S6 peptide kinase in intact rat liver following insulin injection. J Biol Chem 267: 21089–21097, 1992PubMedGoogle Scholar
  63. 63.
    Doria A, Fioretto P, Avogaro A: Insulin resitance is associated with hig sodium-lithium countertransport in essential hypertension. Am J Physiol 261: E684–691, 1991PubMedGoogle Scholar
  64. 64.
    Bhanot S, McNeill JH: Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension 24: 625–632, 1994PubMedGoogle Scholar
  65. 65.
    Bhanot S, McNeill JH, Bryer-Ash M: Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension 23: 308–312, 1994PubMedGoogle Scholar
  66. 66.
    Pontremoli R, Zerbini G, Rivera A, Canessa M: Insulin activation of red blood cell Na+/H+ exchange decreases the affinity of sodium sites. Kidney International 46: 365–375, 1994PubMedCrossRefGoogle Scholar
  67. 67.
    Wolpert HA, Steen SN, Istfan NW, Simonson DC: Disparité effects of weight loss on insulin sensitivity and erythrocyte sodium-lithium countertransport activity. Am J Hypertension 5: 754–757, 1992Google Scholar
  68. 68.
    Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501–2509, 1995PubMedCrossRefGoogle Scholar
  69. 69.
    Blondel O, Bailte D, Portha B: In vivo insulin resistance in streptozotocin-diabetic rats-evidence for reversal following oral vanadate treatment. Diabetologia 32: 185–190, 1989PubMedCrossRefGoogle Scholar
  70. 70.
    Brichard SM, Ongemba LM, Henquin JC: Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35: 522–527, 1992PubMedCrossRefGoogle Scholar
  71. 71.
    Malabu UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat. Diabetes 43: 9–15, 1994PubMedCrossRefGoogle Scholar
  72. 72.
    Olefsky J: The insulin receptor: A multifunctional protein. Diabetes 39: 1008–1016, 1990CrossRefGoogle Scholar
  73. 73.
    Kozma SC, Lane HA, Ferrari S, Luther H, Siegmann M, Thomas G: A stimulated S6 kinase from rat liver; identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J 8: 4125–4132, 1989PubMedGoogle Scholar
  74. 74.
    Azarnoff DL: Site of vanadium inhibition of cholesterol biosynthesis. J Amer Chem Soc 79: 2968, 1957CrossRefGoogle Scholar
  75. 75.
    Hudson TGF: The effects of vanadium on metabolism (continued). In: Anonymous Vanadium: Toxicology and Biological significance. Elselvier Publishing Co., New York, 1964 pp 30–43Google Scholar
  76. 76.
    Mountain JT, Stockell FR, Stokinger HE: Effect of ingested vanadium on cholesterol and phospholipid metabolism in the rabbit. Proc Soc Exp Biol Med 92: 582 1956PubMedGoogle Scholar
  77. 77.
    Curran GL, Costello RL: Reduction of excess cholesterol in the rabbit aorta by inhibition of endogenous cholesterol synthesis. J Exp Med 103: 49 1956PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Allison B. Goldfine
    • 1
  • Donald C. Simonson
    • 1
  • Franco Folli
    • 1
  • Mary-Elizabeth Patti
    • 1
  • C. Ronald Kahn
    • 1
  1. 1.Research Division, Joslin Diabetes Center, Department of MedicineBrigham and Women’s Hospital, and Harvard Medical SchoolBostonUSA

Personalised recommendations